1213O - Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
C. Robert (Villejuif–Paris Sud, France)

1214O - Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
O. Hamid (Los Angeles, United States of America)

Invited Discussant 1213O and 13140
O. Michielin (Lausanne, Switzerland)

1215O - Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
R. Dummer (Zürich, Switzerland)

1216O - KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma
A. Ribas (Los Angeles, United States of America)

Invited Discussant 1215O and 1216O
P. Lorigan (Manchester, United Kingdom)